Related Experiment Video
Updated: Jan 13, 2026

Rapid Generation of Amyloid from Native Proteins In vitro
Published on: December 5, 2013
Acquired and Genetic Amyloid Neuropathies
Chafic Karam1, Mamatha Pasnoor2, Richard J Barohn3
1Neuromuscular Division, Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.
Abstract:
Amyloidosis is a potentially treatable cause of polyneuropathy with various distinct etiologies, including amyloid light chain (AL), transthyretin variant (ATTRv), wild-type transthyretin amyloidosis (wrATTR), gelsolin, and apolipoprotein A1 (ApoA-I). Among these, AL and transthyretin amyloidosis are the most common, while AGel and ApoA-I amyloidosis present more complex diagnostic challenges due to their rarity. Despite advances in the recognition and treatment of AL and transthyretin amyloid protein amyloidosis, diagnostic delays remain a concern. Accurate diagnosis hinges on genetic testing, biomarker development, and tissue biopsy with Congo red staining. Multidisciplinary collaboration, including neurologists, is crucial for optimizing patient outcomes across all forms of amyloidosis.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Parkinson's Disease: Overview
Alzheimer's Disease: Treatment
Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

